Cargando…
Pharmacological modulation of prostaglandin E(2) (PGE(2)) EP receptors improves cardiomyocyte function under hyperglycemic conditions
Type 2 diabetes (T2D) affects >30 million Americans and nearly 70% of individuals with T2D will die from cardiovascular disease (CVD). Circulating levels of the inflammatory signaling lipid, prostaglandin E(2) (PGE(2)), are elevated in the setting of obesity and T2D and are associated with decrea...
Autores principales: | Bosma, Karin J., Ghosh, Monica, Andrei, Spencer R., Zhong, Lin, Dunn, Jennifer C., Ricciardi, Valerie F., Burkett, Juliann B., Hatzopoulos, Antonis K., Damron, Derek S., Gannon, Maureen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995713/ https://www.ncbi.nlm.nih.gov/pubmed/35403369 http://dx.doi.org/10.14814/phy2.15212 |
Ejemplares similares
-
Changing prostaglandin E2 (PGE(2)) signaling during lesional progression and exacerbation of endometriosis by inhibition of PGE(2) receptor EP2 and EP4
por: Huang, Qingqing, et al.
Publicado: (2021) -
Pharmacological blockade of the EP3 prostaglandin E(2) receptor in the setting of type 2 diabetes enhances β-cell proliferation and identity and relieves oxidative damage
por: Bosma, Karin J., et al.
Publicado: (2021) -
Opposing effects of prostaglandin E(2) receptors EP3 and EP4 on mouse and human β-cell survival and proliferation
por: Carboneau, Bethany A., et al.
Publicado: (2017) -
A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE(2)-mediated immunosuppression and inhibits breast cancer metastasis
por: Ma, Xinrong, et al.
Publicado: (2013) -
COX-2-PGE(2)-EPs in gynecological cancers
por: Ye, Yao, et al.
Publicado: (2020)